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Abstract 
Background: Panama has an extensive mangrove area and it is one of the countries with the highest biodiversity 
in America. Mangroves are widely used in traditional medicine, nevertheless, there are very few studies that validates 
their medicinal properties in America. Given the urgent need for therapeutic options to treat several diseases of public 
health importance, mangrove ecosystem could be an interesting source of new bioactive molecules. This study was 
designed to evaluate the potential of Pelliciera rhizophorae as a source of bioactive compounds.
Results: The present investigation was undertaken to explore the possible antiparasitic potential and α‑glucosidase 
inhibition by compounds derived from the Panamanian mangrove Pelliciera rhizophorae. Bioassay‑guided fractiona‑
tion of the crude extract led to the isolation of ten chemical compounds: α‑amyrine (1), β‑amyrine (2), ursolic acid 
(3), oleanolic acid (4), betulinic acid (5), brugierol (6) iso‑brugierol (7), kaempferol (8), quercetin (9), and quercetrin 
(10). The structures of these compounds were established by spectroscopic analyses including APCI‑HR‑MS and 
NMR. Compounds 4 (IC50 = 5.3 µM), 8 (IC50 = 22.9 µM) and 10 (IC50 = 3.4 µM) showed selective antiparasitic activity 
against Leishmania donovani, while compounds 1 (IC50 = 19.0 µM) and 5 (IC50 = 18.0 µM) exhibited selectivity against 
Tripanosoma cruzi and Plasmodium falciparum, respectively. Moreover, compounds 1–5 inhibited α‑glucosidase 
enzyme in a concentration‑dependent manner with IC50 values of 1.45, 0.02, 1.08, 0.98 and 2.37 µM, respectively. 
Their inhibitory activity was higher than that of antidiabetic drug acarbose (IC50 217.7 µM), used as a positive control. 
Kinetic analysis established that the five compounds acted as competitive inhibitors. Docking analysis predicted that 
all triterpenes bind at the same site that acarbose in the human intestinal α‑glucosidase (PDB: 3TOP).
Conclusions: Three groups of compounds were isolated in this study (triterpenes, flavonols and dithiolanes). Trit‑
erpenes and flavones showed activity in at least one bioassay (antiparasitic or α‑glucosidase). In addition, only the 
pentacyclic triterpenes exhibited a competitive type of inhibition against α‑glucosidase.
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Background
Present world is a place of high mortality rates mainly 
due to severe poverty. High levels of poverty results in 
malnutrition, overcrowding, bad sanitation and polluted 
water. These conditions lead to a fertile environment for 
parasitic diseases and diabetes. A parasitic infection is 
one of the leading causes of chronic human diseases in 
most tropical countries. The parasites, including pro-
tozoa and helminthes, infect billions of people and can 
result in blindness, disfigurement, or even death. Efforts 
to develop vaccines against these pathogens have been 
prevented by the difficulty of cultivation of parasites 
in the laboratory, the complexity of their multicellular 
organization and many species have been developing 
impressive antigenic variability. At the same time, most 
treatments involve highly toxic drugs and parasites 
has greatly increased the drug-resistant and finally, the 
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chemotherapeutic agents used in infected patients have 
lacked effectiveness [1–3].
Another major cause of mortality is Diabetes mellitus 
(DM), it was responsible for about 1.5 million deaths in 
2012. According to World Health Organization (WHO) 
forecasts, DM will be the 7th leading cause of death in 
2030, and its prevalence has shown to be higher in low 
and middle-income countries. This disease is known for 
allowing high sugar levels in human blood, either because 
insulin production is inadequate or because the body’s 
cells do not respond properly to insulin, or both. Patients 
with high blood sugar will typically present many fatal 
disorders in different organs, including hyperosmolar 
hyperglycemic nonketotic syndrome, feet and skin com-
plications, amputations, hypertension, retinopathy, neu-
ropathy and diabetic nephropathy [4, 5]. Thus, there is 
an urgent need to search for novel drugs from several 
sources, including natural products, to fight global health 
problems posed by parasitic infections and DM.
In the western hemisphere, mangroves are a natu-
ral source that has been poorly explored for biomedical 
potential. Mangroves are a group of halophytes plants 
that are developed in the tropical or subtropical areas, 
functioning as a bridge between the marine and ter-
restrial habitats. Mangroves are highly adapted to their 
environment and they are able to deal with many physi-
cal stress factors such as strong variation in moisture and 
salt concentrations, changing tides, and biological stress-
ing factors produced by abundant herbivorous insects 
[6]. Currently, mangrove plants and their extracts are 
mainly used by dwellers for medicinal use, especially for 
the treatment skin infections, tuberculosis, skin wounds, 
diarrhea, and other uses such as insecticides and pisci-
cides [6–8]. Mangroves are a good source of secondary 
metabolites such as alkaloids, steroids, flavonoids, sapo-
nins, tannins, and triterpenes. Chemical studies using 
mangrove plants have led to the isolation of over 200 bio-
active compounds [8, 9].
Panama has an extensive mangrove area and it is one 
of the countries with the highest biodiversity in America 
[6]. Mangroves are widely used in traditional medicine, 
nevertheless, there are very few studies that validates 
their medicinal properties in America. Given the urgent 
need for therapeutic options to treat several diseases of 
public health importance, mangrove ecosystem could be 
an interesting source of new bioactive molecules. This 
study was designed to evaluate the potential of Pelliciera 
rhizophorae as a source of bioactive compounds. Here we 
report the isolation, identification and bioactivity against 
three parasites (Leishmania donovani, Plasmodium fal-
ciparum and Trypanosoma cruzi) and the modulation of 
α-glucosidase function of compounds produced by this 
plant, which is endemic mangrove from Central America.
Results
Chemical study
Pelliciera rhizophorae (Pellicieraceae) is an endemic man-
grove plant from the Central American coasts. Mangrove 
leaves were collected in the protected mangrove area of 
Chame Bay, Panama. In the initial screening (against P. 
falciparum, T. cruzi and L. donovani), the crude extract 
did not present antiparasitic activity but it showed good 
inhibition against α-glucosidase enzyme (82  % of inhi-
bition). Following the protocols of our laboratory we 
performed a primary fractionation by open column chro-
matography to afford 37 fractions. All fractions were 
submitted for bioactivity testing, resulting in fractions 
IX (70  % growth inhibition (GI) against T. cruzi), FXIII 
(83 % GI against L. donovani and 69 % GI against P. falci-
parum), FXXVIII (80 % GI against L. donovani, 73 % GI 
against P. falciparum and 67 % GI against T. cruzi), and 
FXXXIII (75 % GI against L. donovani) having antipara-
sitic properties and fractions IX (86  %), FXIII (93  %), 
and FXXXIII (84  %) showed inhibition of α-glucosidase 
activity at a concentrations of 10 µg/mL for parasites and 
6.25 µg/mL for α-glucosidase. Bioassay-guided fractiona-
tion of the active fractions yielded compounds α-amyrine 
(1), β-amyrine (2), ursolic acid (3), oleanolic acid (4), bet-
ulinic acid (5), brugierol (6), iso-brugierol (7), kaempferol 
(8), quercetin (9) and quercetrin (10), which were estab-
lished by spectroscopic analyses including APCI-HR-MS 
and NMR (1H, 13C, DEPT 135, DEPT 90, COSY, NOESY, 
HMBC and HMQC). The structures (Fig.  1) were cor-
roborated by comparing the spectroscopic and spec-
trometric data with those previously reported [10–18]. 
Even though the isolated compounds are quite common 
compounds, and are found in many other plant species, 
it should be emphasized that this is the first report about 
the occurrence of triterpenes, flavonoids and dithiolanes 
in the genus Pelliciera. Therefore, this plant represents a 
new source of this type of bioactive substances, which in 
several studies they have shown beneficial properties for 
human health.
Antiparasitic activity
Compounds 3, 4, 8, 9 and 10 displayed biological activ-
ity against the amastigotes of L. donovani (Table 1). This 
result was expected mainly because in previous reports 
ursolic acid showed activity against the promastigotes of 
L. donovani [19], oleanolic acid inhibited the promastig-
otes of L. braziliensis and L. chagasi [20], while querce-
tin, kaempferol and quercetrin displayed a leishmanicidal 
effect on the amastigote stage of L. donovani [19, 21, 22]. 
Moreover, compounds 3, 5 and 9 were active against a 
chloroquine-resistant strain (Indochina W2) of P. falci-
parum. These compounds had previously shown activity 
against P. falciparum chloroquine-sensitive 3D7 (3, 5 and 
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9) and chloroquine-resistant K1 (9) [19, 23]. Finally, com-
pounds 1 and 9 also showed bioactivity against T. cruzi, 
strain Tulahuen, clone C4 (Table  1). These compounds 
had previously exhibited activity against trypomastigotes 
of T. brucei rhodesiense which causes African trypanoso-
miasis [24, 25].
Although the antiparasitic activity of the isolated 
compounds is not comparable to that of controls, it is 
important to emphasize two important aspects, first 
the isolated compounds were evaluated against three 
different parasites of human importance so it is possible 
to describe some selectivity in the activity of P. rhizopho-
rae components, and second these compounds showed 
low levels of cytotoxicity. According to this, compounds 
1, 4, 5, 8 and 10 have selective activity against one para-
site while compound 9 possess broad activity inhibiting 
the three evaluated parasites. Nevertheless, the main 
trouble with these compounds will be their low polar-
ity, which gives them aqueous solubility problems, and 
therefore low absorption and limited bioavailability. 
Developing analogues with higher polarity and better 
biological activity would be a viable option to overcome 
this obstacle.
Infectious diseases, including causative agents of tryp-
anosomiasis, leishmaniasis and malaria, are responsi-
ble for a high rate of mortality and morbidity each year 
in the countries with high levels of poverty. Due to the 
lack of treatment options, there is an urgent need to dis-
cover novel therapeutics options against these neglected 
tropical diseases. Thus, the discovery of new sources of 
antiparasitic agents is of great significance, because natu-
ral sources are one of the most affordable, especially for 
people in poor countries.
α‑Glucosidase inhibition evaluation and kinetic studies
Triterpenes 1–5 inhibited α-glucosidase enzyme in a con-
centration-dependent manner with IC50 values of 1.45, 
0.02, 1.08, 0.98 and 2.37 µM, respectively. All triterpenes 
were more potent against α-glucosidase than acarbose 
(positive control, IC50 217.7  µM). Given the structural 
Fig. 1 Structures of compounds produced by Pelliciera rhizophorae
Table 1 Antiparasitic activity (IC50, μM) of  the isolated 
compounds from Pelliciera rhizophorae
I inactive at 10 µg/mL, ND not determined
Compounds L. donovani P. falciparum T. cruzi Vero cells
1 I I 19.0 ± 0.6 I
2 I I I I
3 2.4 ± 0.1 21.9 ± 0.6 I 64.8 ± 0.3
4 5.3 ± 0.2 I I 140.8 ± 0.5
5 I 18.0 ± 0.4 I 131.1 ± 0.3
6 I I I I
7 I I I I
8 22.9 ± 0.2 I I 154.9 ± 0.6
9 12.6 ± 0.2 9.7 ± 0.3 13.0 ± 0.4 I
10 3.4 ± 0.1 I I I
Anfotericine B 1.0 ± 0.12 ND ND ND
Chloroquine ND 0.09 ± 0.01 ND ND
Nifurtimox ND ND 1.6 ± 0.11 ND
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similarities and biological activity among compounds 
1–5, the minor substitutions of the central core (pentacy-
clic triterpene) does not appear to produce a significant 
difference in the α-glucosidase inhibition. However, if we 
compare compound 2 with the other compounds, it can 
be inferred that presence of a gem dimethyl at position 20 
and a methyl in position 28, it confer a potent inhibitory 
activity to the pentacyclic core.
In order to obtain further evidence of the nature of 
the interaction of compounds 1–5 with α-glucosidase 
kinetic analyses were carried out. Lineweaver–Burk plots 
[26] were constructed using different concentrations of 
substrate and triterpenes 1–5. The results in Fig. 2 indi-
cated that 1–5 showed typical reversible competitive 
plots, with series of lines having the same y-intercept as 
the enzyme without inhibitors. These results suggested 
that compounds 1–5 bind to α-glucosidase or to the 
substrate-enzyme complex. Acarbose also behaved as 
competitive inhibitor [27]. These results show that penta-
cyclic triterpene core is a potent competitive inhibitor of 
the α-glucosidase enzyme.
With respect to the modulations of α-glucosidase func-
tion by compounds 6–10, metabolites 8 (262.2 µM) and 
9 (29.8 µM) showed moderate inhibition while 6, 7 and 
10 were inactive, so it can be hypothesized the main 
α-glucosidase inhibitors produced by P. rhizophorae 
belongs to pentacyclic triterpenoid family.
Docking study
Taking into account the preliminary in  vitro 
α-glucosidase inhibition evaluations, the most active 
compounds (pentacyclic triterpenes) were selected to 
explain the experimental activities. Based on this, molec-
ular docking study was conducted to evaluate the puta-
tive binding mode of compounds 1–5 into the human 
intestinal α-glucosidase (PDB: 3TOP). Results indicate 
that all analyzed triterpenoid compounds bind mainly 
through hydrophobic interactions. Figure  3 shows the 
superposition of docking poses of compounds 1–5 and 
acarbose in the binding site. It is interesting to note that 
despite analyzed triterpenoids are mainly hydrophobic, 
they bind into the same site of acarbose that is a more 
polar compound. As expected, acarbose interacts with 
the binding site through many hydrogen bonds (Fig. 4a) 
and compounds 1–5 interact via hydrophobic interac-
tions (Fig.  4b). However, all triterpenoids interact with 
Lys 1460 through formation of hydrogen bonds with 
3β-OH group or via ionic interaction between the car-
boxylate group in the triterpenoid and the amine group 
of Lys 1460 (Fig. 5a, b). This interaction has some signifi-
cance for enzyme inhibition since docking poses where 
the 3β-OH-Lys hydrogen bond interaction was present 
had lower scores than docking poses with the carboxy-
late-Lys ionic interaction (see Table  2). In fact, docking 
poses with lower scores for compound 5 always displayed 
an ionic interaction with Lys 1460. Poses of compound 5 
have fewer hydrophobic interactions than poses of com-
pounds 1–4, and this could be a plausible explanation for 
its lower enzyme inhibition in comparison with the other 
compounds analyzed. Therefore, taking compound 5 as 
an outlier, there is a slight correlation between docking 
score and experimental IC50.
Conclusions
In summary, ten compounds were isolated from the 
endemic mangrove P. rhizophorae (five triterpenes, three 
flavonols and two dithiolanes). Dithiolane is the only 
core of the three evaluated lacking antiparasitic activity. 
Even though all compounds reported in this work have 
been reported from other sources, this is the first report 
of secondary metabolites produced by P. rhizophorae. 
There have been few new options for the treatment of 
neglected tropical diseases in half a century, therefore it 
is important to search for new sources of antiparasitic 
compounds to help global programs aimed at combating 
neglected diseases. P. rhizophorae represents a new natu-
ral source against parasitic protozoans which produces 
several compounds with selective activity (compounds 1, 
4, 5, 8 and 10) and low levels of cytotoxicity. In addition, 
five pentacyclic triterpenes with potent α-glucosidase 
inhibitory activity were isolated. These compounds 
exhibited a competitive type of inhibition against S. cere-
visiae α-glucosidase. All triterpenes showed higher inhib-
itory activity than acarbose. Definitely, in vitro inhibitory 
properties against α-glucosidase enzyme are far superior 
to the antiparasitic properties of this plant. Therefore this 
plant might also be an interesting alternative for reducing 
levels of blood sugar of people affected by DM.
Methods
General experimental procedures
Melting point measurements were carried out on an 
Electrothermal apparatus and are uncorrected. NMR 
spectra were acquired on Jeol Eclipse 400  MHz. APCI-
HR-MS were acquired on a JEOL LC-mate mass spec-
trometer. The purification of the compounds was carried 
out on Agilent 1100 HPLC system equipped with a 
quaternary pump, a diode array detector and a reverse 
phase silica gel column (Phenomenex Synergy Hydro-RP, 
250 mm × 100 mm, 4 μm) or normal phase silica gel col-
umn (Sphereclone silica 250 × 10 mm column) at a flow 
rate of 1.0  mL/min. TLC was performed on precoated 
silica gel 60 F254 plates (Merck). All solvents were HPLC 
grade and used without further purification [3, 28].
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Plant material and extract preparation
P. rhizophorae (Pellicieraceae) leaves were collected at 
Punta Chame, Panama, in May 2012. This plant was 
identified by Alejandro De Sedas. A voucher specimen 
(105833) has been deposited at the University of Panama 
Herbarium. After drying the fresh leaves and crushing 
in a standard blender to obtain 108 g of coarse powder, 
the extract was prepared by maceration with a mixture of 
Fig. 2 Lineweaver–Burk plots of α‑glucosidase inhibition at different concentrations of substrate, compounds 1–5 and acarbose
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MeOH:CHCl3 (1:1). Extract was concentrated to a semi-
solid paste using a Buchi Rotary Evaporator (R-215) to 
obtain 31 g of crude extract.
Isolation of compounds
The organic extract was fractionated by column chro-
matography on silica gel (100 g). The column was eluted 
Fig. 3 Superposition of docking poses of compounds 1–5 (in white) and acarbose (in red)
Fig. 4 Comparision between the interaction of acarbose (a) and compound 2 (b) with glucosidase active site
Fig. 5 Docking poses of compound 2 (a) and compound 3 (b). Interaction with Lys 1460 is highlighted
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with hexane, followed by a gradient of hexane:EtOAc 
(1:0 → 0:1) and finally with a gradient of EtOAc:MeOH 
(1:0  →  1:1). Altogether, 325 fractions (100  ml each) 
were collected and combined according to their TLC 
profiles to yield 37 primary fractions (FI to FXXXVII). 
Fraction FIX (5.77  g) was further subjected to silica gel 
column chromatography and eluted with a gradient of 
hexane:EtOAc (1:0 → 0:1). This process led to 17 second-
ary fractions (FIX-A to FIX-Q). Fraction FIX-D (407 mg) 
eluted with Hexane:EtOAc (8:2), was purified by nor-
mal phase HPLC (Sphereclone silica 250 ×  10 mm col-
umn, isocratic elution of 90 % hexanes:10 % EtOAc, UV 
detector at 254  nm, flow of 1  mL/min) to afford 21  mg 
of α-amyrine (1) and 13  mg of β-amyrine (2). Fraction 
FXIII (773 mg) eluted with Hexane:EtOAc (1:1), purified 
by normal phase HPLC (Sphereclone silica 250 × 10 mm 
column, isocratic elution of 85  % hexanes:15  % EtOAc, 
UV detector at 254 nm, flow of 1 mL/min) yielded 37 mg 
of ursolic acid (3), 27 mg of oleanolic acid (4) and 7 mg 
of betulinic acid (5). Fraction FXXVIII (1.78 g) was fur-
ther subjected to silica gel column chromatography and 
eluted with a gradient of hexane:EtOAc (1:1 → 0:1) and 
EtOAc:MeOH (1:0  →  1:1). This process led to six sec-
ondary fractions (FXXVIII-A to FXXVIII-F). Fraction 
FXXVIII-A (98  mg) eluted with hexane:EtOAc (1:1) 
was purified by normal phase HPLC (Sphereclone silica 
250  ×  10  mm column, isocratic elution of 25  % hex-
anes:75 % EtOAc, UV detector at 254 nm, flow of 1 mL/
min) resulted in 2 mg of brugierol (6) and 1.3 mg of iso-
brugierol (7). Fraction FXXVIII-C (165  mg) eluted with 
100 % EtOAc, was purified by reverse phase HPLC (Syn-
ergi Hydro-RP 250  ×  10  mm column, isocratic elution 
of 40 % MeOH:60 % H2O, UV detector at 254 nm, flow 
of 1.0  mL/min) to afford 3.4  mg of Kaempferol (8) and 
5.0 mg of quercetin (9). Finally, fraction FXXXIII (95 mg), 
eluted with EtOAc:MeOH (1:1), was purified by reverse 
phase HPLC (Synergi Hydro-RP 250 ×  10  mm column, 
isocratic elution of 65 % MeOH:35 % H2O, UV detector 
at 254 nm, flow of 1.0 mL/min) yielded 8 mg of querce-
trin (10).
Spectral compounds data
α-amyrin (1) Colorless solid. m.p. 185–187 °C. 1H-NMR 
(CDCl3, 400  MHz): δH 5.16 (t, J  =  3.6  Hz), 3.23 (dd, 
J = 4.4, 3.9 Hz), 1.96 (td, J = 4.4, 13.6 Hz), 1.85 (m), 1.78 
(td, J = 4.9, 13.6 Hz), 1.00 (s), 0.97 (s), 0.94 (s), 0.87 (s), 
0.83 (d, J = 6.0 Hz), 0.79 (sb) 0.74 (d, J = 11.0 Hz). 13C-
NMR (100 MHz, CDCl3): δC 38.8 (C-1), 28.6 (C-2), 79.3 
(C-3), 38.8 (C-4), 55.2 (C-5), 18.3 (C-6), 32.4 (C-7), 40.6 
(C-8), 47.7 (C-9), 36.9 (C-10), 23.3 (C-11), 124.4 (C-12), 
139.6 (C-13), 42.1 (C-14), 27.3 (C-15), 26.6 (C-16), 
33.7 (C-17), 59.1 (C-18), 39.6 (C-19), 39.7 (C-20), 31.2 
(C-21), 41.5 (C-22), 28.1 (C-23), 15.7 (C-24), 15.6 (C-25), 
16.8 (C-26), 23.3 (C-27), 28.1 (C-28), 17.5 (C-29), 21.4 
(C-30). APCI-HR-MS m/z 427.3893 [M + H]+ (calcd for 
C30H51O, 427.3895).
β-amyrin (2) Colorless solid. m.p. 196-197  °C. 1H-
NMR (CDCl3, 400 MHz): δH 5.18 (t, J = 3.5 Hz), 3.20 (dd, 
J = 4.4, 10.8 Hz), 1.90 (td, J = 4.0, 13.6 Hz), 1.81 (m), 1.73 
(td, J = 4.2, 13.6 Hz), 1.19 (s), 1.09 (s), 0.96 (s), 0.93 (s), 
0.92 (d, J = 6.4 Hz), 0.84 (s), 0.80 (s), 0.72 (d, J = 10.8 Hz). 
13C-NMR (100  MHz, CDCl3): δC 38.6 (C-1), 27.2 (C-2), 
79.0 (C-3), 38.8 (C-4), 54.9 (C-5), 18.4 (C-6), 32.6 (C-7), 
39.8 (C-8), 47.7 (C-9), 36.8 (C-10), 23.5 (C-11), 121.7 
(C-12), 145.2 (C-13), 41.7 (C-14), 26.1 (C-15), 27.2 (C-16), 
32.5 (C-17), 47.3 (C-18), 46.8 (C-19), 31.2 (C-20), 34.7 
(C-21), 37.1 (C-22), 28.1 (C-23), 15.6 (C-24), 15.7 (C-25), 
16.9 (C-26), 25.8 (C-27), 28.4 (C-28), 33.7 (C-29), 23.7 
(C-30). APCI-HR-MS m/z 427.3896 [M + H]+ (calcd for 
C30H51O, 427.3895).
Ursolic acid (3). Colorless solid. m.p. 291–292  °C. 1H 
NMR (CDCl3, 400 MHz): δH 5.28 (t, J = 3.6 Hz), 3.21 (dd, 
J = 10.2, 4.4 Hz), 2.18 (d, J = 11.7 Hz), 1.19 (m), 2.00 (dd, 
J = 13.0, 4.0 Hz), 1.25 (s), 0.98 (s), 0.77 (s), 1.08 (s), 1.14 
(s), 0.93 (d, J =  6.5  Hz), 0.91 (d, J =  5.9  Hz). 13C NMR 
(CDCl3,100  MHz): δC 39.2 (C-1), 27.5 (C-2), 78.5 (C-3), 
38.7 (C-4), 55.5 (C-5), 18.3 (C-6), 33.1 (C-7), 39.6 (C-8), 
47.8 (C-9), 36.9 (C-10), 16.6 (C-11), 125.7 (C-12), 138.4 
(C-13), 41.7 (C-14), 29.5 (C-15), 24.1 (C-16), 47.7 (C-17), 
53.1 (C-18), 39.2 (C-19), 39.2 (C-20), 30.5 (C-21), 36.9 
(C-22), 28.0 (C-23), 15.2 (C-24), 14.8 (C-25), 16.4 (C-26), 
23.1 (C-27), 180.4 (C-28), 22.9 (C-29), 22.8 (C-30). APCI-
HR-MS m/z 457.3635 [M  +  H]+ (calcd for C30H49O3, 
457.3637).
Oleanolic acid (4) Colorless solid. UV (MeOH) m.p. 
299–301  °C.; 1H NMR (CDCl3, 400  MHz): δH 5.24 (t, 
J = 3.6 Hz), 3.21 (dd, J = 10.2, 4.4 Hz), 2.82 (dd, J = 12.7, 
4.3 Hz), 0.96 (s), 0.78 (s), 0.84 (s), 0.76 (s), 1.25 (s), 0.87 
(s), 0.93 (s). 13C NMR (CDCl3, 100  MHz): δC38.6 (C-1), 
26.7 (C-2), 78.5 (C-3), 39.2 (C-4), 55.5 (C-5), 18.3 (C-6), 
32.6 (C-7), 39.6 (C-8), 48.1 (C-9), 37.0 (C-10), 22.7 (C-11), 
122.4 (C-12), 144.1 (C-13), 42.0 (C-14), 27.7 (C-15), 22.8 
(C-16), 46.7 (C-17), 41.5 (C-18), 46.1 (C-19), 30.4 (C-20), 
33.7 (C-21), 32.3 (C-22), 28.8 (C-23), 14.7 (C-24), 15.1 
Table 2 Rerank scores obtained during docking studies
Compound IC50 (mM) Rerank score Interaction 
with Lys 1420
1 1.45 33.4917 Hydrogen bond
2 0.02 −55.6135 Hydrogen bond
3 1.08 −6.54481 Ionic
4 0.98 −24.732 Hydrogen bond
5 2.37 −14.5051 Ionic
r2 0.3195
r2 (5 as outlier) 0.8642
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(C-25), 16.5 (C-26), 25.2 (C-27),180.4 (C-28), 32.8 (C-29), 
23.3 (C-30). APCI-HR-MS m/z 457.3639 [M + H]+ (calcd 
for C30H49O3, 457.3637).
Betulinic acid (5) Colorless solid. m.p. 317–319 °C. 1H 
NMR (CDCl3, 400 MHz): δH 4.66 (s), 3.79 (dd, J = 10.0, 
5.5 Hz), 2.39 (m), 2.10–2.20 (m) 1.66 (s), 1.00 (s), 0.96 (s), 
0.94 (s), 0.80 (s), 0.74 (s). 13C NMR (CDCl3, 100 MHz): δC 
38.9 (C-1), 27.8 (C-2), 79.0 (C-3), 38.7 (C-4), 55.5 (C-5), 
18.3 (C-6), 34.0 (C-7), 40.9 (C-8), 50.4 (C-9), 37.3 (C-10), 
20.7 (C-11), 25.2 (C-12), 37.3 (C-13), 42.7 (C-14), 30.1 
(C-15), 29.3 (C-16), 56.5 (C-17), 46.4 (C-18), 49.1 (C-19), 
150.4 (C-20), 29.8 (C-21), 34.1 (C-22), 28.0 (C-23), 15.4 
(C-24), 16.0 (C-25), 16.1 (C-26), 14.8 (C-27), 180.0 (C-28), 
109.6 (C-29), 19.1 (C-30). APCI-HR-MS m/z 457.3636 
[M + H]+ (calcd for C30H49O3, 457.3637).
Quercetin (6) Yellow powder, m.p. 313–315. 1H NMR 
(DMSO-D6, 400 MHz) δH 6.19 (d, J = 2.0, H-6), 6.41 (d, 
J = 2.0, H-8), 7.69 (d, J = 2.2, H-2′), 6.89 (d, J = 8.5, H-5′), 
7.55 (d, J = 8.5, 2.2, H-6′), 12.98 (1H, s, 5-OH). 13C NMR 
(DMSO-D6, 100 MHz) δC 145.1 (C-2), 135.8 (C3), 175.9 
(C-4), 103.1 (C-4a), 160.8 (C-5), 98.3 (C-6), 164.0 (C-7), 
93.41 (C-8), 156.2 (C-9), 122.0 (C-1′), 115.10 (C-2′), 146.9 
(C-3′), 147.8 (C-4′), 115.7 (C-5′), 120.1 (C-6′). APCI-
HR-MS m/z 303.0569 [M  +  H]+ (calcd for C15H10O7, 
303.0505).
Kaempferol (7) Pale yellow needles, m.p. 276–278  °C. 
1H NMR (DMSO-D6, 400  MHz) δH 6.19 (d, J  =  1.9, 
H-6), 6.45 (d, J =  1.9, H-8), 8.04 (d, J =  8.9, H-2′), 6.93 
(d, J = 8.9, H-3′), 6.93 (d, J = 8.9, H-5′), 8.04 (d, J = 8.9, 
H-6′), 9.35 (br s, 3-OH), 10.10 (br s, 4-OH), 12.48 (br s, 
5OH), 10.85 (s, 7-OH). 13C NMR (DMSO-D6, 100 MHz) 
δc: 148.1 (C-2), 137.3 (C-3), 177.6 (C-4), 104.5 (C-4a), 
162.8 (C-5), 99.3 (C-6), 165.5 (C-7), 94.5 (C-8), 160.7 
(C-8a), 123.9 (C-1), 130.9 (C-2), 116.5 (C-3), 158.3 (C-4), 
116.4 (C-5), 130.9 (C-6) APCI-HR-MS m/z 287.0606 
[M + H]+ (calcd for C15H11O6, 287.0556).
Quercetrin (8) Amorphous yellow powder, m.p. 
181–182  °C, 1H NMR (DMSO-D6, 400  MHz): δH 
7.36 (dd, J =  1.8, 8.1  Hz), 7.30 (d, J =  1.8  Hz), 6.87 (d, 
J = 8.4 Hz), 6.40 (d, J = 1.8 Hz), 6.21 (d, J = 2.2 Hz), 5.25 
(d, J = 1.5 Hz), 4.20 (m), 3.73 (dd, J = 3.4, 9.2 Hz), 3.38 
(m), 3.31 (m), 0.90 (d, J = 6.6 Hz); 13C NMR (DMSO-D6, 
100 MHz): δC 178.1 (C-4), 164.8 (C-7), 161.9 (C-5), 157.5 
(C-9), 157.0, (C-2) 149.0 (C-3′), 145.8 (C-4′), 134.8 (C-3), 
121.6 (C-1′), 121.2 (C-6′), 116.2 (C-2′), 116.0 (C-5′), 104.7 
(C-10), 102.4 (C-1″), 99.2 (C-6), 94.2 (C-8), 71.5 (C-5″), 
71.2 (C-3″), 70.9 (C-2″), 70.6 (C-4″), 18.1 (C-6″); APCI-
HR-MS m/z 449.1079 [M  +  H]+, C21H21O11 calcd for 
449.1084).
Brugierol (9) Colorless solid, m.p. 88–89  °C, 1H 
NMR (CD3Cl, 400  MHz): δH 5.23 (bs, H-4), 3.74 (dd, 
J =  11.0, 6.0, H-5b), 3.53 (dd, J =  12.0, 6.0, H-3a), 3.41 
(dd, J =  12.0, 2.1, H-3b), 3.34 (dd, J =  11.0, 6.0, H-5a). 
13C (CD3Cl, 100  MHz): δC 43.3 (C-3), 75.8 (C-4), 70.0 
(C-5). APCI-HR-MS m/z 139.9770 [M + H]+ (calcd for 
C3H7O2S2, 139.9767).
Iso-brugierol (10) Colorless solid, m.p. 82–83  °C, 1H 
NMR (CD3Cl, 400  MHz): δH 4.71 (bs, H-4), 4.10 (dd, 
J =  10.5, 1.0, H-5b), 4.08 (dd, J =  13.0, 1.0, H-3b), 3.63 
(dd, J =  10.5, 3.8, H-5a), 3.02 (dd, J =  13.0, 3.8, H-5b). 
13C (CD3Cl, 100  MHz): δC 48.1 (C-3), 80.2 (C-4), 67.8 
(C-5). APCI-HR-MS m/z 139.9764 [M + H]+ (calcd for 
C3H7O2S2, 139.9767).
Culture procedure
Promastigotes cultures of L. donovani are maintained in 
continuous log phase growth in Liver Infusion Tryptose 
(LIT) Medium, pH 7.2, supplemented with 10  % Fetal 
Bovine Serum (FBS) at 28  °C. For promastigote trans-
formation into amastigote forms, 1 mL of promastigotes 
log phase culture is transferred into 5 mL of Medium 199 
Modified (SIGMA-Cat M3769) pH 5.5, supplemented 
with 0.1 g/L l-glutamine, 2.2 g/L sodium bicarbonate, 2 g 
Glucose, 5 mL penicillin–streptomycin and 20 % FBS and 
maintained at 35 °C until its use for bioassays.
Antiplasmodial activity is evaluated using a chloro-
quine-resistant strain (Indochina W2) of P. falciparum. 
The cultures are kept in synchrony by thermal cycling 
incubation [29] and are maintained in continuous log 
phase growth in RPM-I1640 medium (SIGMA) sup-
plemented with 2  % washed human O Rh positive (+) 
erythrocytes, 25 mM HEPES, 32 nM NaHCO3, and 10 % 
Human Serum from an O Rh+ donor. All cultures and 
assays are conducted at 37  °C under an atmosphere of 
5 % CO2 and 5 % O2, with a balance of N2 (90 %).
T. cruzi (Tulahuen) C4 strain lactosidase (Lac Z) gene 
[30]. The strain is maintained on VERO Cells (African 
Green Monkey cell line obtained from ATCC on 2006), 
grown in monolayers in RPM-I1640 medium, supple-
mented with 10 % heat inactivated FBS. All cultures and 
assays are conducted at 37  °C under an atmosphere of 
5 % CO2/95 % air mixture.
In vitro antiparasitic assays
Dry samples were diluted in 100  % DMSO (dimethyl-
sulfoxide) to obtain a concentration of 4  mg/mL. Sam-
ples are used immediately in the bioassay and stored at 
−20  °C in the dark until results are obtained. All assays 
are performed in sterile 96-well microtitre culture plates 
(Costar Cat 3595). In a primary screening samples are 
tested in duplicate wells at a final concentration of 10 μg/
mL. If activity is found (growth Inhibition >75  % for L. 
donovani and P. falciparum and growth Inhibition >50 % 
for T. cruzi) then an assessment of the concentration that 
inhibits 50  % of growth (IC50) is carried out with four 
concentrations, by duplicates. The IC50 is analyzed with 
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the Excel Add-On software LSW Data Analysis Tool. The 
concentration that inhibited the growth of the parasites 
to 50 % (IC50) was calculated through the inhibition curve 
of the obtained optical density values, and compared to 
the untreated controls.
L. donovani and P. falciparum A DNA cross linking 
agent is used to determine the amount of parasites in 
culture. After 48 and 72  h incubation, respectively, 1  % 
PicoGreen® solution is added to all wells in the dark. 
After shaking, the plate is taken into a microplate reader 
employing 485/20 nm excitation and 528/20 nm emission 
filter sets. Amphotericin B was used as a positive control 
for Leishmania; the typical IC50 response of L. donovani 
to this drug is 70–120  ng/μl. Chloroquine served as a 
positive control for P. falciparum (IC50  =  80–100  nM) 
[3].
T. cruzi In this assay, a colorimetric method is used to 
determine the inhibition of parasite growth as detected 
by reduction of β-galactosidase (β-Gal) as a reporter 
gene, expressed by the Tulahuen clone C4 of T. cruzi [22]. 
Assays are performed on trypomastigotes, the intracellu-
lar form of the parasite infecting African green monkey 
kidney (VERO) cells, exposed during 120  h to different 
concentrations (50, 10 and 2  µg/mL) of the test sub-
stance. The resulting colour from the cleavage of chloro-
phenol red-β-d-galactoside (CPRG) by β-Gal expressed 
by the parasite, was measured using a Benchmark Bio-
Rad microplate reader at 570 nm. Nifurtimox was used as 
a positive control (IC50 0.15–13.4 µM) [3, 31].
Cytotoxicity bioassay
Vero cells were seeded in 96-well plates in RPM-I1640 
medium supplemented with 10  % FBS and 1  % penicil-
lin/streptomycin. The cells were allowed to grow for 24 h 
before adding the test compounds, dissolved in DMSO, 
to final concentrations of 10, 4, 0.2 and 0.08  µg/mL. A 
sample with only a volume of DMSO similar to the added 
volume in the compounds samples was placed as a nega-
tive control in all plates. All samples were incubated for 
five days before staining and examining for reduction of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) and analyzed 4  h later in a color plate 
reader at 570 nm.
α‑Glucosidase inhibitory assay
The α-glucosidase inhibitory assay was performed 
according to Chan and collaborators (2010) [32], with 
modifications. α-glucosidase from baker’s yeast pur-
chased from Sigma Chemical Co. The inhibition was 
measured spectrophotometrically at pH 7.0 and 37  °C 
employing 2  mM p-nitrophenyl α-d-glucopyranoside 
(PNP-G) as a substrate and 32  mU/mL of enzyme, in 
100  mM potassium phosphate buffer (enzyme stock). 
Acarbose was dissolved in phosphate buffer, and serial 
dilutions (in order to obtain the IC50) were prepared 
and employed as positive control. The absorbance (A) of 
4-nitrophenol released by the hydrolysis of PNP-G was 
measured at 400 nm by Synergy HT Bio Tek microplate 
spectrophotometer. A 20  µL of acarbose or test com-
pounds solution was incubated for 7 min with 150 µL of 
enzyme stock at 37  °C. After incubating, 150µL of sub-
strate was added and further incubated for 20  min at 
37  °C. All assays are performed in 96-well microplates 
(Greiner bio-one 655101) in duplicate. The activity of 
samples was calculated as a percentage in comparison to 
a control (DMSO or MeOH instead of sample solution) 
according with the following equation:
The concentration required to inhibit activity of the 
enzyme by 50 % (IC50) was calculated by regression anal-
ysis [33].
Docking study
All ligands were constructed in Spartan’10 [34], and 
their geometry was optimized using MMFF force field. 
Protein–ligand docking studies were carried out based 
on the crystal structures for C-terminal domain of 
human intestinal α-glucosidase (PDB: 3TOP) [35] which 
was retrieved from the Protein Data Bank [36]. Prior to 
docking, all of the solvent molecules and the co-crystal-
lized ligand was removed. Molecular docking calcula-
tions were performed using Molegro Virtual Docker v. 
6.0.1 [37]. A sphere of 15 Å radius was centered in the 
binding site for searching. Experimental data indicates 
that these compounds are competitive inhibitors; thus 
the active site was chosen as the binding site. Protona-
tion states and assignments of the charges on each pro-
tein were based on standard templates as part of the 
Molegro Virtual Docker program, and no other charges 
were necessary to set. Flexible ligand models were used 
in the docking and subsequent optimization scheme. 
Different orientations of the ligands were searched and 
ranked based on their energy scores. The RMSD thresh-
old for multiple cluster poses was set to <1.00 Å. The 
docking algorithm was set to 5000 maximum iterations 
with a simplex evolution population size of 100 and a 
minimum of 50 runs for each ligand. After docking, a 
number of further scores were calculated including the 
binding affinity (MolDock Score) and re-ranking score 
(Rerank Score). The re-ranking score utilizes a more 
advanced scoring scheme than that used during dock-
ing and is often more useful for accurate ranking of the 




(� Acontrol −� Asample)/� Acontrol
)
× 100 %
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To assess the efficacy of this procedure for finding low 
energy solutions, the co-crystallized ligand (acarbose) 
was also docked. The top ranking score was recorded, 
and the RMSD of that pose from the corresponding crys-
tal coordinates calculated. RMSD was lower than 2Å, 
indicating that the methodology used in the molecular 
docking simulation is appropriate.
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